Catalyst Pharmaceuticals Inc (CPRX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 49.46% | 53.84% | 54.81% | 54.37% | 56.51% | 54.48% | 52.53% | 50.28% | 49.22% | 48.21% | 48.34% | 46.35% | 48.54% | 63.57% | 65.23% | 66.45% | 73.20% | 62.28% | 55.48% | 38.32% |
| Operating profit margin | 21.80% | 21.79% | 45.62% | 46.82% | 47.54% | 43.69% | 42.64% | 39.00% | 37.20% | 36.14% | 36.22% | 33.63% | 34.69% | 34.43% | 35.77% | 36.57% | 31.11% | 12.35% | -31.24% | -234.40% |
| Pretax margin | 23.73% | 23.20% | 47.81% | 48.57% | 48.89% | 44.08% | 42.58% | 39.19% | 37.40% | 36.38% | 36.44% | 33.91% | 35.18% | 35.18% | 36.80% | 37.89% | 32.66% | 14.45% | -27.70% | -223.58% |
| Net profit margin | 17.93% | 17.81% | 38.14% | 38.76% | 38.79% | 34.90% | 31.97% | 29.31% | 28.03% | 31.16% | 58.80% | 60.11% | 62.97% | 60.48% | 34.87% | 36.09% | 31.16% | 12.99% | -28.78% | -223.58% |
Catalyst Pharmaceuticals Inc's profitability ratios have shown fluctuations over the past few quarters. The gross profit margin has ranged from 38.32% to 73.20%, indicating variability in the efficiency of production and cost management.
The operating profit margin has also been volatile, ranging from -234.40% to 47.54%. This suggests fluctuations in operational efficiency and cost-control measures.
The pretax margin has varied between -27.70% and 48.89%, indicating significant volatility in the company's profitability before taxes.
Lastly, the net profit margin has shown fluctuations between -28.78% and 62.97%, reflecting variability in the company's profitability after all expenses, including taxes, have been accounted for.
Overall, the profitability ratios of Catalyst Pharmaceuticals Inc indicate significant fluctuations, highlighting the need for the company to focus on improving cost management, operational efficiency, and overall profitability sustainability. Additional analysis of the company's cost structure and revenue drivers may be necessary to address these fluctuations and improve overall profitability.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 18.47% | 18.37% | 31.14% | 29.49% | 27.11% | 25.15% | 27.19% | 24.27% | 22.03% | 21.62% | 21.98% | 20.49% | 21.47% | 23.27% | 32.60% | 36.91% | 28.32% | 9.28% | -16.69% | -49.69% |
| Return on assets (ROA) | 15.19% | 15.01% | 26.03% | 24.41% | 22.12% | 20.09% | 20.39% | 18.24% | 16.60% | 18.64% | 35.68% | 36.62% | 38.98% | 40.88% | 31.78% | 36.43% | 28.36% | 9.77% | -15.37% | -47.40% |
| Return on total capital | 22.38% | 21.78% | 36.83% | 35.99% | 33.90% | 31.02% | 30.15% | 27.22% | 25.33% | 24.29% | 24.33% | 22.62% | 24.35% | 25.98% | 38.52% | 43.65% | 36.32% | 11.51% | -20.63% | -59.31% |
| Return on equity (ROE) | 18.41% | 17.80% | 30.79% | 29.79% | 27.65% | 24.78% | 22.60% | 20.46% | 19.09% | 20.95% | 39.49% | 40.43% | 44.21% | 45.63% | 37.56% | 43.09% | 36.37% | 12.11% | -19.00% | -56.57% |
Catalyst Pharmaceuticals Inc has shown a consistent improvement in profitability ratios over the recent quarters. The operating return on assets (Operating ROA) has been steadily increasing, indicating the company's ability to generate profits from its operational assets. The return on assets (ROA) and return on total capital have also demonstrated an upward trend, showcasing efficient utilization of assets and capital to generate earnings.
Furthermore, the return on equity (ROE) has shown a positive trajectory, reflecting the company's ability to generate profits for its shareholders. These profitability ratios suggest that Catalyst Pharmaceuticals Inc is effectively managing its resources to generate returns for both operational and capital investments.
Overall, the improving profitability ratios indicate that Catalyst Pharmaceuticals Inc is on a positive growth trajectory and is enhancing its financial performance, which could be a positive signal for investors and stakeholders.